Cargando…

A promising inactivated whole-virion SARS-CoV-2 vaccine

Detalles Bibliográficos
Autores principales:	Isakova-Sivak, Irina, Rudenko, Larisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561316/ https://www.ncbi.nlm.nih.gov/pubmed/33069282 http://dx.doi.org/10.1016/S1473-3099(20)30832-X

Ejemplares similares

Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests
por: Rak, Alexandra, et al.
Publicado: (2022)

RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples
por: Goshina, Arina, et al.
Publicado: (2023)

Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview
por: Kudryavtsev, Igor, et al.
Publicado: (2022)

In Vitro Stimulation with Live SARS-CoV-2 Suggests Th17 Dominance In Virus-Specific CD4+ T Cell Response after COVID-19
por: Kudryavtsev, Igor, et al.
Publicado: (2022)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model
por: Rak, Alexandra, et al.
Publicado: (2023)

M2e-based universal influenza vaccines: a historical overview and new approaches to development
por: Mezhenskaya, Daria, et al.
Publicado: (2019)

Ferristatin II Efficiently Inhibits SARS-CoV-2 Replication in Vero Cells
por: Sokolov, Alexey, et al.
Publicado: (2022)

Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories
por: Rudenko, Larisa, et al.
Publicado: (2016)

Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus
por: Stepanova, Ekaterina, et al.
Publicado: (2020)

Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination
por: Tavukcuoglu, Ece, et al.
Publicado: (2023)

Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure
por: Loveday, Emma K., et al.
Publicado: (2021)

Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
por: Li, Jing-Xin, et al.
Publicado: (2021)

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
por: Ganneru, Brunda, et al.
Publicado: (2021)

A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice
por: Tokunoh, Nagisa, et al.
Publicado: (2023)

Detection of IFNγ-Secreting CD4(+) and CD8(+) Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2
por: Matyushenko, Victoria, et al.
Publicado: (2021)

Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine
por: Matyushenko, Victoria, et al.
Publicado: (2017)

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine
por: Chaiwarith, Romanee, et al.
Publicado: (2023)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine
por: Kennedy, Richard B
Publicado: (2022)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

SARS-CoV-2 and HIV-1 — a tale of two vaccines
por: Haynes, Barton F.
Publicado: (2021)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_omhdqopcaiud2ufom6covkq03f